MARKET

SCYX

SCYX

Scynexis
NASDAQ
2.450
0.000
0.00%
After Hours: 2.530 +0.08 +3.27% 16:50 11/25 EST
OPEN
2.450
PREV CLOSE
2.450
HIGH
2.470
LOW
2.430
VOLUME
100.46K
TURNOVER
0
52 WEEK HIGH
8.10
52 WEEK LOW
1.700
MARKET CAP
80.01M
P/E (TTM)
-1.1236
1D
5D
1M
3M
1Y
5Y
SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats
BARDA is seeking to support the development of broad-spectrum, oral/IV antifungal drug candidates with novel mechanisms of action that target Candida species, including Candida auris, and Aspergillus species.Ibrexafungerp, a first-in-class, broad-spectrum ...
GlobeNewswire · 11/17 13:30
SCYNEXIS Q3 EPS $(0.62) Misses $(0.50) Estimate, Sales $1.56M Miss $2.07M Estimate
Benzinga · 11/09 12:21
SCYNEXIS GAAP EPS of -$0.62 misses by $0.12, revenue of $1.56M misses by $0.5M
Seekingalpha · 11/09 12:07
-- Earnings Flash (SCYX) SCYNEXIS Posts Q3 Revenue $1.6M, vs. Street Est of $2.1M
-- Earnings Flash (SCYX) SCYNEXIS Posts Q3 Revenue $1.6M, vs. Street Est of $2.1M
MT Newswires · 11/09 07:08
Notable earnings before Wednesday's open
Seekingalpha · 11/08 15:36
SCYNEXIS Announces Publication Of Review Article Highlighting Ibrexafungerp As A Potential Novel Treatment For Invasive Mold Infections In The Journal Of Fungi
Benzinga · 11/07 13:31
BRIEF-Pooled Data From The Pivotal Phase 3 Vanish Program Published In The Journal Of Women’S Health
Reuters · 11/03 12:45
Pooled Data From The Pivotal Phase 3 VANISH Program Published In The Journal Of Women's Health Demonstrate Significant Efficacy Of Ibrexafungerp Over Placebo For Treatment Of Vaginal Yeast Infection
Benzinga · 11/03 12:33
More
About SCYX
SCYNEXIS, Inc. is a biotechnology company. The Company is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (IV)/oral agent for multiple fungal indications in both the community and hospital settings. It has received the approval from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) for BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection). BREXAFEMME is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC). It is also continuing late-stage clinical development of ibrexafungerp for multiple indications, including the treatment of life-threatening invasive fungal infections in hospitalized patients.

Webull offers kinds of SCYNEXIS Inc stock information, including NASDAQ:SCYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCYX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SCYX stock methods without spending real money on the virtual paper trading platform.